



Q&M's Acumen Diagnostics wins Ministry of Health (MOH) tender for operation of a Joint Testing & Vaccination Center (JTVC)

- *Operations to commence on 21 November 2022 with estimated revenue of at least S\$3.6 million*
- *Singapore's success in controlling COVID-19 ensures economy remains open and livelihoods protected*
- *Private medical sector's operation of Joint Testing & Vaccination Centers is part of Government's move to ensure the population always has convenient access to COVID-19 testing & vaccination facilities*

Singapore, 11 October 2022 – Homegrown medical technology Company, **Acumen Diagnostics Pte. Ltd.** (“Acumen Diagnostics” “Acumen” or the “Company”), a 51% owned subsidiary of **Q & M Dental Group(Singapore) Limited** (“Q & M Dental”) and 49% owned by **Aoxin Q & M Dental Group Limited** (“AoxinQ & M Dental”), today announced that it has recently won a Singapore Ministry of Health (MOH) tender for the operation of one of the sites allocated for Joint Testing and Vaccination Centers¹ (JTVC). The operation of JTVCs by the private medical sector is part of the Government's policy and efforts to provide the public with efficient and convenient access to COVID-19 booster shot vaccination.

Acumen's 15-month contract commences on 1 October 2022 and ends on 31 December 2023, with actual operations starting from 21 November 22. The value of the contract over the period is estimated to be worth at least S\$3.6 million.

Dr Ong Siew Hwa (王秀华博士), Chief Executive Officer & Chief Scientist of Acumen Diagnostics and Executive Director of Aoxin Q & M Dental, said *“It is vitally important to keep the population safe and the Singapore economy open to protect livelihoods. Periodic COVID-19 booster shots as a preventive measure to counter the natural waning of immunity over time remains the best strategy to achieve this and we are pleased to be able to play our part in the Government's overall COVID-19 strategy.”*

¹ JTVC Reference: <https://www.moh.gov.sg/covid-19/jtvc>



Dr Ng Chin Siau (黄震霄医生), Chief Executive Officer Q & M Dental said, *“We are honoured that Acumen has been selected to operate one of the JTVCs, and with our highly trained and experienced staff, we will be able to provide members of the public with a safe and comfortable environment when getting their booster shots. This is one way that we can help to encourage everyone to take their booster shots when required,.”* so as to maintain a high level of immunity against the COVID-19 virus.”

- End -

About Acumen Diagnostics Pte. Ltd. (www.acumen-research.com)

Acumen Diagnostics Pte. Ltd. (“Acumen Diagnostics”) is a homegrown Singaporean, award-winning medical technology company. It is fully integrated with functions in research and development, manufacturing, as well as commercialisation of molecular diagnostics by distribution as well as conducting clinical laboratory testing services for (including but not limited to) infectious diseases, cancer, and COVID-19. It has also actively established frontline services such as COVID-19 on-site swabbing operations.

Acumen Diagnostics is a 51% subsidiary of SGX-listed Q & M Dental Group (Singapore) Limited (SGX: 1D4.SI) and 49%-owned by SGX-listed Aoxin Q & M Dental Group Limited (SGX: QC7.SI).

About Q & M Dental Group (Singapore) Limited (QC7.SI) (www.QandMDental.com.sg)

Q & M Dental Group (Singapore) Limited (QC7.SI) (“Q & M” or together with its subsidiaries, the “Group”) is a leading private dental healthcare group in Asia.

The Group owns the largest network of private dental outlets in Singapore, operating 106 dental outlets across the country. Underpinned by about 270 experienced dentists and over 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.

Outside of Singapore, the Group has 45 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People’s Republic of China (“PRC”). Q & M is also the substantial shareholder of Aoxin Q & M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange that operates dental clinics and hospitals primarily in the north-eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within the ASEAN region.

The Q & M College of Dentistry was established in 2019 to offer postgraduate dental education as part of its commitment to continual education and professional development of dentists. It offers Singapore’s first private postgraduate diploma programme in clinical dentistry.

In 2020, the Group expanded into the medical laboratories and research industry with the strategic investment into Acumen Diagnostics Pte. Ltd. (“Acumen”). Acumen currently focuses on the manufacture, sale and distribution of COVID-19 diagnostic test kits, as well as COVID-19 testing. It is also working to roll out a pipeline of new tests, including PCR assays for dengue, sepsis and, identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.



EM2AI Pte Ltd, a wholly-owned subsidiary of the Group that focuses on developing AI-powered solutions to diagnosis and treatment planning has rolled out IDMS, enabling dentists within the Group's network to administer ethical treatment plans for patients.

The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX-ST") on 26 November 2009. **About Aoxin Q & M Dental Group Limited** (Stock Code: 1D4.SI) (www.aoxinqm.com.sg)

Aoxin Q & M Dental Group Limited ("Aoxin Q & M" or together with its subsidiaries, the "Group") is a leading provider of private dental services in the Liaoning Province, Northern People's Republic of China ("PRC"). The Group operates 16 dental centres, comprising 10 dental polyclinics and 6 dental hospitals, located across 8 cities in Liaoning Province, namely Shenyang, Huludao, Panjin, Gaizhou, Zhuanghe, Jinzhou, Dalian and Anshan.

We currently have 400 dental professionals, including 170 dentists, 180 dental surgery assistants and 50 laboratory technicians.

A majority of the dental centres are accredited as Designated Medical Institutions of Medical Insurance. Additionally, the Group is engaged in the provision of dental laboratory services, as well as the distribution and sale of dental equipment and supplies in the Liaoning, Heilongjiang and Jilin Provinces in Northern PRC.

Aoxin Q & M was listed on the Catalist board of the Singapore Exchange Securities Trading Limited on 26 April 2017. Media and Analysts: please contact below for more information:

For more information, please contact:

Waterbrooks Consultants Pte Ltd

Wayne Koo - wayne.koo@waterbrooks.com.sg +65 9338-8166

Derek Yeo - derek@waterbrooks.com.sg +65 9791-4707

Proud Investor Relations partner: <https://www.waterbrooks.com.sg/> and <https://www.shareinvestorholdings.com/>